Answers are grounded in this paper and cite their sources.
BACKGROUND: Electrographic flow (EGF) mapping allows for the near real-time visualization of atrial wavefront propagation. Two factors have been found to be associated with higher rates of atrial fibrillation (AF) recurrence: presence of active extra-pulmonary vein (PV) sources and low electrographic flow consistency (EGFC) representing chaotic flow and abnormal atrial substrate. Based on these characteristics, EGF phenotypes have been identified: Type I patients have no sources + high EGFC, Type II have sources + high EGFC, Type III have sources + low EGFC, and Type IV have no sources + low EGFC. OBJECTIVE: Determine the sex differences in EGF phenotypes and post-ablation outcomes. METHODS: Patients were pooled from three prospective clinical trials: FLOW-AF, EVAL-AF, and the AF-FLOW Global Registry. From these trials, 104 persistent AF (PeAF) or long-standing PeAF patients underwent EGF mapping in 5 standardized, biatrial basket positions. Phenotyping into one of the 4 types was performed from post-PVI maps, and patients were followed for up to 12 months post-procedure, which included PVI-only and PVI + EGF-guided source ablation procedures. Outcomes were compared by chi-square tests, z-tests of proportions, logistic regression, and cox proportional models. CONCLUSIONS: Female patients with PeAF are more likely to have extra-PV sources but healthy underlying substrate (Type II), which responds favorably to PVI + targeted source ablation. Ablation strategies should consequently target an individual's mechanism of disease. TRIAL REGISTRATION NUMBERS: FLOW-AF: NCT04473963, FLOW EVAL-AF: NCT06260670, AF-FLOW Global Registry: NCT05481359.
No takes yet. Share an insight, caveat, or question.
Kutinsky et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: